ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a press ...

Looking ahead, ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.

ALX CEO Warren Stanyer will join Greenridge as president and director. The merger is also expected to yield significant cost ...